An evidence-based examination of THC delivery methods, CBD dosing protocols, therapeutic mechanisms, and legal frameworks across DC and Virginia.

A landmark investigation reveals Oregon’s licensed psilocybin service centers are exceeding safety and compliance standards, but economic barriers limit broader access.

An in-depth look at Ascend Cannabis in downtown Cincinnati, product delivery methods, scientific pharmacokinetics, and lessons for DMV consumers.

An in-depth look at Midtown Phoenix's Story Cannabis, exploring retail formats, cannabinoid science, safety, and takeaways for DMV consumers.

The end of a Dutch health ministry supply contract forces the legacy medical cannabis pioneer into bankruptcy, shifting global market dynamics.

European pilot programs prove legal cannabis delivery can work. Here’s how Switzerland and the Netherlands are informing Virginia’s evolving marijuana regulations.

Federal rescheduling fuels cannabis M&A, but integration—not deal size—decides who thrives. What this shift means for Virginia, DC, and Maryland weed delivery laws.

A major study finds marijuana use rivals prescription meds for those attempting to quit smoking cigarettes, raising new questions for Virginia, DC, and Maryland residents.

A new study shows cannabis is the leading substance used among U.S. hikers—surpassing alcohol and psychedelics. Scientific context, safety, and DMV region implications explored.

New policy research reveals that interactive regulatory QR codes significantly boost consumer trust, safety awareness, and legal market participation.

A large, placebo-controlled study reported meaningful back pain relief and better sleep with a low-dose THC medication—without signs of dependency.

Blackwell Captive teams with Apta Health to add a guided cash‑pay option for employers in its programs, including Humboldt Health, aiming to simplify access and cost control.

High Times reports a small clinical trial of an experimental medication for cannabis withdrawal. Here’s what we know now, how it could work, and what DMV patients should watch.

A Minnesota state analysis of 1,811 autism patients found sustained reductions in moderate-to-severe anxiety and depression after joining the medical cannabis program, with improvements often lasting at least four months.

The FDA opened a 45‑day comment window on how to safely study ibogaine, seeking input on dosing, cardiac monitoring, ethics, and trial design—without touching legalization debates.

Georgia regulators greenlight home delivery for registered patients and permit university research with state-program products—changes that could reshape access and evidence-building.

A University of Michigan–led analysis reported in Annals of Internal Medicine finds a 16% rise since 2020 in U.S. clinicians authorizing medical cannabis, with millions of patients participating.

Oregon pauses a proposed psilocybin fee increase, California earmarks $4.7M for psychedelic research, and the DEA moves to schedule five tryptamines—here’s why it matters.

A December 18, 2025 executive order shifts cannabis from Schedule I to Schedule III. Here’s how that could reshape taxes, research, and patient access across the DMV.

A landmark Phase 2 study will test smoked, high-THC flower versus placebo in 320 veteran participants with moderate to severe PTSD. Here’s what’s being studied and why it matters for DMV patients.